Midkine characterization in human ovaries: potential new variants in follicles.

MDK gene midkine protein oocyte maturation preovulatory follicles small antral follicles

Journal

F&S science
ISSN: 2666-335X
Titre abrégé: F S Sci
Pays: United States
ID NLM: 101765857

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 14 07 2023
revised: 15 09 2023
accepted: 15 09 2023
medline: 20 11 2023
pubmed: 23 9 2023
entrez: 22 9 2023
Statut: ppublish

Résumé

To characterize the growth factor midkine (MDK) in the human ovary to determine whether MDK is produced locally within the ovary, examine whether different ovarian cell types are more likely to produce MDK, and determine whether there are any stage-specific variations during follicle growth. Previous studies have revealed that MDK potentially affects human follicle growth and oocyte maturation. Proteomic analyses in follicular fluid (FF) have identified MDK to functionally cluster together and follow a similar expression profile to that of well-known proteins involved in ovarian follicle development. Midkine has not yet been characterized in the human ovary. Descriptive study. University Hospital. The study included samples from 121 patients: 71 patients (aged 17-37 years) who underwent ovarian tissue cryopreservation provided granulosa cells (GC), cumulus cells, ovarian cortex, medulla tissue, and FF from small antral follicles (SAF); and 50 patients (aged 20-35 years) receiving in vitro fertilization treatment provided FF from preovulatory follicles before and after induction of final follicle maturation. None. MDK relative gene expression was quantified using a real-time quantitative polymerase chain reaction in cumulus cells, GC, and medulla tissue. Additionally, immunostaining and western blotting assays were used to detect MDK protein in the ovarian cortex, which contains preantral follicles, SAF, and medulla tissue. Furthermore, enzyme-linked immunosorbent assay analyses were performed to measure the concentration of MDK in FF aspirated from SAF and preovulatory follicles both before and 36 hours after inducing the final maturation of follicles. Immunostaining and reverse transcription-quantitative polymerase chain reaction revealed a more prominent expression of MDK in GC compared with other ovarian cell types. Intrafollicular MDK concentration was significantly higher in SAF compared with preovulatory follicles. In addition, different molecular weight species of MDK were detected using western blotting in various ovarian sample types: GC and FF samples presented primarily one band of approximately 15 kDa and an additional band of approximately 13 kDa, although other bands with higher molecular weight (between 30 and 38 kDa) were detected in medulla tissue. This is the first time that MDK has been immunolocalized in human ovarian cells at the protein level and that potentially different MDK variants have been detected in human FF, GC, and ovarian medulla tissue. Future studies are needed to sequence and identify the different potential MDK variants found to determine their functional importance for ovary and oocyte competence.

Identifiants

pubmed: 37739342
pii: S2666-335X(23)00051-4
doi: 10.1016/j.xfss.2023.09.003
pii:
doi:

Substances chimiques

Midkine 137497-38-2
MDK protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

294-301

Informations de copyright

Copyright © 2023 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests J.C. has nothing to disclose. S.E.P. has nothing to disclose. C.P.H. has nothing to disclose. S.M.O. has nothing to disclose. C.S. has nothing to disclose. J.A.B. has nothing to disclose. L.L.C.P. has nothing to disclose. J.F. has nothing to disclose. M.D. has nothing to disclose. L.B.C. has nothing to disclose. S.G.K. has nothing to disclose. L.S.M. has nothing to disclose. C.Y.A. has nothing to disclose.

Auteurs

Jesús Cadenas (J)

Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children, and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. Electronic address: jesus.cadenas.moreno@regionh.dk.

Susanne Elisabeth Pors (SE)

Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children, and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Caroline Pulz Hansen (CP)

Department of Science and Environment, Roskilde University, Roskilde, Denmark.

Sarah Maria Olufsen (SM)

Department of Science and Environment, Roskilde University, Roskilde, Denmark.

Cristina Subiran (C)

Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children, and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Jane Alrø Bøtkjær (JA)

Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children, and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Liv La Cour Poulsen (L)

The Fertility Clinic, Copenhagen University Hospital, Herlev Hospital, Borgmester Ib Juuls Vej 9, Herlev, Denmark.

Jens Fedder (J)

Centre of Andrology and Fertility Clinic, Odense University Hospital, Odense, Denmark; Research Unit of Human Reproduction, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Margit Dueholm (M)

Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark.

Lotte Berdiin Colmorn (LB)

The Fertility Clinic, University Hospital of Copenhagen, Copenhagen, Denmark.

Stine Gry Kristensen (SG)

Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children, and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Linn Salto Mamsen (LS)

Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children, and Reproduction, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.

Claus Yding Andersen (CY)

The Department of Clinical Medicine, Faculty of Health and Medical Science, Copenhagen University, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH